demecolcine and Leukemia--Erythroblastic--Acute

Previous work from this laboratory has shown that Friend's murine erythroleukemia cells (MELCs) express some bio-chemical traits of the megakaryocytic lineage. The supposed mixed erythroid/megakaryocytic nature of these cells has been investigated further by challenging MELCs with the antimicrotubule agent colcemid. This compound, at the concentration of 40 nM, was found to induce a striking arrest of cell growth without significant effects on viability. At the same time, the bulk of treated MELCs underwent a large increase in size to contain, after 3 days, as much as 4 times more proteins and 5 times more DNA than controls. As shown by high rates of 3H-thymidine incorporation, increase in DNA content was the result of active synthesis without completion of intervening mitosis according to a process that closely resembled endoreplication. Eventually, colcemidinduced MELCs presented multilobed nuclei and were arranged into discrete ploidy groups containing up to 16 N levels of DNA. Moreover, upon colcemid addition, MELCs initiated a polyploid response that was shown to continue, even in the absence of the inducer, to yield cells that became strongly positive for acetylcholinesterase (AChE) in the late stages of culture. These effects were compatible with a colcemid-induced commitment of MELCs to megakaryocyte differentiation, for which these cells seemed to be definitely programmed. The expression of megakaryocyte features in MELCs provided further evidence for the bipotentiality (erythroid/megakaryocytic) of this model.

Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Size; Cell Survival; Demecolcine; DNA; Flow Cytometry; Friend murine leukemia virus; Leukemia, Erythroblastic, Acute; Megakaryocytes; Mice; Ploidies; Time Factors; Tumor Cells, Cultured

The cell cycle has been shown to regulate the biological effects of human tumor necrosis factor (TNF), but to what extent that regulation is due to the modulation of TNF receptors is not clear. In the present report we investigated the effect of the cell cycle on the expression of surface and soluble TNF receptors in human histiocytic lymphoma U-937. Exposure to hydroxyurea, thymidine, etoposide, bisbensimide, and demecolcine lead to accumulation of cells primarily in G1/S, S, S/G2/M, G2/M, and M stages of the cell cycle, respectively. While no significant change in TNF receptors occurred in cells arrested in G1/S or S/G2 stages, about a 50% decrease was observed in cells at M phase of the cycle. Scatchard analysis showed a reduction in receptor number rather than affinity. In contrast, cells arrested at S phase (thymidine) showed an 80% increase in receptor number. The decrease in the TNF receptors was not due to changes in cell size or protein synthesis. The increase in receptors, however, correlated with an increase in total protein synthesis (to 3.8-fold of the control levels). A proportional change was observed in the p60 and p80 forms of the TNF receptors. A decrease in the surface receptors in cells arrested in M phase correlated with an increase in the amount of soluble receptors. The cellular response to TNF increased to 8- and 2-fold in cells arrested in G1 and S phase, respectively; but cells at G2/M phase showed about 6-fold decrease in response. In conclusion, our results demonstrate that the cell cycle plays an important role in regulation of cell-surface and soluble TNF receptors and also in the modulation of cellular response.

Topics: Cell Cycle; Demecolcine; DNA; Enzyme Inhibitors; Etoposide; G1 Phase; G2 Phase; HeLa Cells; Humans; Hydroxyurea; Leukemia, Erythroblastic, Acute; Lymphoma, Large B-Cell, Diffuse; Mitosis; Nocodazole; Receptors, Tumor Necrosis Factor; S Phase; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vinblastine

In previous studies, it was shown that treatment of Friend erythroleukemia (FEL) cells with dimethylsulfoxide (DMSO) and the poly(ADP-ribose) polymerase inhibitor 3-aminobenzamide (3AB) blocked the differentiation pathway just prior to commitment. These studies show that the exposure of DMSO(+3AB)-induced cells to the mitotic inhibitors colcemid or nocodazole resulted in commitment to terminal differentiation. Expression of differentiated phenotype required further incubation without the mitotic inhibitors. Microscopic examination indicated that the number of cells blocked in mitosis and those that differentiated were approximately equivalent. These observations suggest that commitment had occurred during mitosis and that expression of the differentiated state occurred after completion of mitosis. Since commitment was not inhibited by blocking DNA replication by aphidicolin or cytokinesis by cytochalasin B, mitosis may be the only phase of the cell cycle required for commitment.

Topics: Aphidicolin; Benzamides; Cell Survival; Demecolcine; Dimethyl Sulfoxide; Diterpenes; Erythrocytes; Hematopoiesis; Leukemia, Erythroblastic, Acute; Mitosis; Nocodazole; Phenotype; Tumor Cells, Cultured